# A clinic visit can clarify your next step *A clinic visit | PRP Injections Glendale* > When joint soreness needs a clinic visit, what happens during the exam, what to bring, and which warning signs need prompt care. When is joint soreness worth a clinic visit? Book an exam when it lingers or limits your usual day. Go sooner if the joint changes suddenly. The visit can find where the soreness begins and which care may fit. ## The visit starts with your description of the soreness You will be asked when the ache started and what brings it on. Say whether the joint feels stiff, swollen, or unsteady. Mention an old injury even if it happened long ago. The clinician will check how the joint moves and where it hurts. Imaging means pictures from an earlier scan, which may also be reviewed. The exam helps separate a joint problem from soreness in a nearby tendon. It also gives you time to describe your daily limits. ## Some warning signs need prompt care A joint that feels hot and swollen during fever may be infected. Spreading redness or pus after a treatment also needs urgent care. Don't wait for a regular appointment when these signs appear. After an injury, get prompt help if you can't put weight on the joint. A joint that looks bent or out of place also needs urgent care. These problems need an exam before any planned treatment. ## A short note helps you prepare for the exam Write down the tasks that worsen soreness, every medicine you use, and any past care. Take the available pictures from earlier joint scans. Your note keeps useful facts close during the visit. Ask what the exam showed and what you can do before treatment. If PRP comes up, the term means platelet-rich plasma made from your blood. Also ask about movement after treatment and which changes mean you need to call. ## Sources 1. The DEPA classification was built because platelet and leukocyte counts alone do not describe an injection. Applied retrospectively to 20 published PRP preparations, the dose of injected platelets ranged from 0.21 billion to 5.43 billion - a 25-fold spread. No device recovered more than 90% of the platelets in the blood drawn, and most preparations were contaminated with red blood cells: only three of the devices reached a purity score corresponding to more than 90% platelets relative to red cells and leukocytes. Magalon J, Chateau AL, Bertrand B, et al. — [DEPA classification: a proposal for standardising PRP use and a retrospective application of available devices](https://pubmed.ncbi.nlm.nih.gov/27900152/). *BMJ Open Sport & Exercise Medicine*, 2016. DOI: 10.1136/bmjsem-2015-000060. 2. A systematic review of 105 clinical PRP studies in orthopaedics published 2006-2016 found that only 11 (10%) described the preparation protocol clearly enough for another investigator to repeat it, and only 17 (16%) reported any quantitative metric of the final PRP composition. The authors concluded that the current reporting of PRP preparation and composition does not allow the PRP products actually delivered to patients to be compared between studies. Chahla J, Cinque ME, Piuzzi NS, et al. — [A Call for Standardization in Platelet-Rich Plasma Preparation Protocols and Composition Reporting: A Systematic Review of the Clinical Orthopaedic Literature](https://pubmed.ncbi.nlm.nih.gov/29040132/). *Journal of Bone and Joint Surgery (American)*, 2017. DOI: 10.2106/JBJS.16.01374. 3. A Delphi consensus of 24 invited experts produced the Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO) checklists: 58 items reached consensus for PRP and were compiled into a 23-statement reporting checklist, with a parallel 25-statement checklist for mesenchymal stem cells. The need for it was identified because clinical studies of PRP and MSCs are 'limited by inadequate reporting of scientific details critical to outcome'. Murray IR, Geeslin AG, Goudie EB, et al. — [Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO): Platelet-Rich Plasma and Mesenchymal Stem Cells](https://pubmed.ncbi.nlm.nih.gov/28509821/). *Journal of Bone and Joint Surgery (American)*, 2017. DOI: 10.2106/JBJS.16.00793. 4. A systematic review that screened 876 studies and extracted standardised data from 33 commercially available PRP systems and protocols found that final product concentrations of platelets, white cells and growth factors varied widely between systems, as did the preparation protocols themselves. Platelet concentration correlated directly with the volume of blood drawn and with the centrifugal force of the device. The authors called the heterogeneity between separation systems something that 'must be resolved for proper study of this promising treatment'. Fadadu PP, Mazzola AJ, Hunter CW, et al. — [Review of concentration yields in commercially available platelet-rich plasma (PRP) systems: a call for PRP standardization](https://pubmed.ncbi.nlm.nih.gov/30992411/). *Regional Anesthesia and Pain Medicine*, 2019. DOI: 10.1136/rapm-2018-100356. 5. The American Academy of Physical Medicine and Rehabilitation convened a technical expert panel that ran a structured literature review (2023, updated through June 2025) and a modified Delphi process, and issued five evidence-based clinical recommendations plus 11 consensus-based best practices for PRP in knee osteoarthritis. The statement is explicit that orthobiologic therapies 'remain an evolving area of practice' and that robust, dose-dependent randomized controlled trials are still needed to establish PRP's clinical effects. Borg-Stein J, Jayaram P, Colorado BS, et al. — [AAPM&R guidance statement on platelet rich plasma for knee osteoarthritis](https://pubmed.ncbi.nlm.nih.gov/41989317/). *PM&R*, 2026. DOI: 10.1002/pmrj.70144. 6. The ESSKA-ICRS consensus applied the RAND/UCLA appropriateness method to 216 clinical scenarios for intra-articular PRP in knee OA. Only 84 scenarios (38.9%) were rated appropriate, 9 (4.2%) inappropriate and 123 (56.9%) uncertain. PRP was judged appropriate in patients aged 80 or under with KL grade 0-III osteoarthritis AFTER failed conservative non-injective or injective treatment; it was NOT considered appropriate as a first treatment, nor in KL grade IV (bone-on-bone) osteoarthritis, where 91.7% and 87.5% of scenarios respectively were uncertain. Kon E, de Girolamo L, Laver L, et al. — [Platelet-rich plasma injections for the management of knee osteoarthritis: The ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios](https://pubmed.ncbi.nlm.nih.gov/38961773/). *Knee Surgery, Sports Traumatology, Arthroscopy*, 2024. DOI: 10.1002/ksa.12320. ## An exam comes before a treatment choice QC Kinetix medical providers, the clinicians who examine your joint, may discuss regenerative treatments, meaning non-surgical care such as concentrated PRP made from your blood. Book a free consultation: --- Understand the soreness and what you can do. Learn why joints ache, ways to ease soreness, signs needing care, and how your blood becomes PRP. Plain help with joint soreness, blood-based PRP, and nearby care in Glendale. This site is operated by the owners of the QC Kinetix clinics serving the Phoenix area, including the Peoria and Banner Estrella offices these pages point readers toward — so read it as first-party writing from a business that benefits when you book, and check every figure against the sources listed on each page. Copyright 2026 The West Valley Platelet Count. General education about platelet-rich plasma and joint pain, not medical advice about your own joint; talk to a clinician who can examine it.